Stang, A. & Jöckel, K. H. The impact of cancer screening on all-cause mortality: what is the best we can expect? Dtsch. Arztebl Int. 115, 481–486 (2018).

PubMed  PubMed Central  Google Scholar 

Loeb, S. et al. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 65, 1046–1055 (2014).

PubMed  PubMed Central  Article  Google Scholar 

Aizer, A. A. et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J. Natl Compr. Cancer Netw. 13, 61–68 (2015).

Article  Google Scholar 

Wang, M. C. et al. Purification of a human prostate specific antigen. Investig. Urol. 17, 159–163 (1979).

CAS  Google Scholar 

Papsidero, L. D. et al. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40, 2428–2432 (1980).

CAS  PubMed  Google Scholar 

Kuriyama, M. et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 40, 4658–4662 (1980).

CAS  PubMed  Google Scholar 

Kuriyama, M. et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 41, 3874–3876 (1981).

CAS  PubMed  Google Scholar 

Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J. & Ratliff, T. L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J. Urol. 154, 407–413 (1995).

CAS  PubMed  Article  Google Scholar 

Ming-Chu, T. Prostate specific antigen (PSA): the historical perspective. MJM https://doi.org/10.26443/mjm.v2i2.564 (1996).

Article  Google Scholar 

Chu, T. M., Wang M. C. & Papsidero, L. Purified human prostate antigen United States Patent and Trademark Office. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PTXT&s1=316954.AP.&OS=APN/316954&RS=APN/316954 (1984).

Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 (1987).

CAS  PubMed  Article  Google Scholar 

Roth, J. A., Gulati, R., Gore, J. L., Cooperberg, M. R. & Etzioni, R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. 2, 890–898 (2016).

PubMed  PubMed Central  Article  Google Scholar 

Catalona, W. J. et al. Measurement of prostate-specific antigen serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991).

CAS  PubMed  Article  Google Scholar 

Thompson, I. M., Ernst, J. J., Gangai, M. P. & Spence, C. R. Adenocarcinoma of the prostate: results of routine urological screening. J. Urol. 132, 690–692 (1984).

CAS  PubMed  Article  Google Scholar 

Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).

PubMed  Article  Google Scholar 

Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hsing, A. W., Tsao, L. & Devesa, S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60–67 (2000).

CAS  PubMed  Article  Google Scholar 

RGHM Cremers, H. E. et al. Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989–2006. Eur. J. Urol. 46, 2077–2087 (2010).

Google Scholar 

Roobol, M. J., Kirkels, W. J. & Schöder, F. H. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int https://doi.org/10.1111/j.1464-410X.2003.04390.x (2004).

Article  Google Scholar 

National Cancer Institute. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). NIH https://prevention.cancer.gov/major-programs/prostate-lung-colorectal-and-ovarian-cancer-screening-trial (2020).

The European Randomized study of Screening for Prostate Cancer. ERSPC Background. ERSPC https://www.erspc.org/prostate-cancer/erspc-background/#study-protocol (2021).

Schröder, F. H. & Roobol, M. J. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur. Urol. 58, 46–52 (2010).

PubMed  Article  Google Scholar 

de Koning, H. J. et al. The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials. Cancer 124, 1197–1206 (2018).

PubMed  Article  Google Scholar 

Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality — the future of PSA screening. N. Engl. J. Med. 382, 1557–1563 (2020).

PubMed  Article  Google Scholar 

Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77, 38–52 (2020).

PubMed  Article  Google Scholar 

Carioli, G. et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann. Oncol. 31, 650–658 (2020).

CAS  PubMed  Article  Google Scholar 

Sung, H. et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 71, 209–249 (2021).

Google Scholar 

U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann. Intern. Med. 137, 915–916 (2002).

Article  Google Scholar 

U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 149, 185–191 (2008).

Article  Google Scholar 

Moyer, V. A. Screening for Prostate Cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).

PubMed  Article  Google Scholar 

Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J. Natl Inst. 113, 64–71 (2021).

Article  Google Scholar 

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Prostate cancer screening with the PSA test. IQWIG https://www.iqwig.de/projekte/s19-01.html (2020).

UK National Screening Committee. Screening for prostate cancer. UK National Screening Committee https://view-health-screening-recommendations.service.gov.uk/document/424/download (2020).

Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362, K3519 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Tikkinen, K. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ 362, K3581 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Lenzen-Schulte, M. Prostatakrebs-screening: Prüffall PSA-test. Dtsch. Arztebl 117, 1–2 (2020).

Google Scholar 

Shoag, J. E., Mittal, S., Hu, J. C. & Reevaluating, P. S. A. Testing rates in the PLCO trial. N. Engl. J. Med. 374, 1795–1796 (2016).

PubMed  Article  Google Scholar 

Tsodikov, A. et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann. Intern. Med. 167, 449–455 (2017).

PubMed  PubMed Central  Article  Google Scholar 

Grossman, D. C. et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319, 1901–1913 (2018).

PubMed  Article  Google Scholar 

European Association of Urology. Archive of the Prostate Cancer guideline. EAU https://uroweb.org/guidelines/archive/prostate-cancer (2020).

Martin, R. M. et al. CAP Trial Group effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319, 883–895 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Hugosson, J. et al. Eighteen-year follow-up of the Göteborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand. J. Urol. 52, 27–37 (2018).

PubMed  Article  Google Scholar 

Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43–51 (2019).

PubMed  PubMed Central  Article  Google Scholar 

Pinsky, P. F. et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 123, 854–860 (2019).

PubMed  Article  Google Scholar 

Roobol., M. J. Screening for prostate cancer: are organized screening programs necessary? Trans. Androl. Urol. 7, 4–11 (2018).

Article  Google Scholar 

Heijnsdijk, E. A. M. et al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med. 367, 595–605 (2012).

CAS  PubMed  PubMed Central  Article  Google Scholar 

RIZIV/INAMI, National Institute for Health and Disability Insurance (NIHDI), Nomenclature of medical acts in Belgium, Chapter V, 11 clinical biology (2021).

Heidenreich, A. et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur. Urol. 64, 347–354 (2013).

PubMed  Article  Google Scholar 

Yard, D. H. PSA testing: why the U.S. and Europe differ. Renal & Urology News https://www.renalandurologynews.com/home/news/urology/prostate-cancer/psa-testing-why-the-u-s-and-europe-differ/ (2011).

Ciatto, S. et al. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int. 92 (Suppl 2), 97–100 (2003).

PubMed  Article  Google Scholar 

Pinsky, P. F. et al. Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Clin. Trials 7, 303–311 (2010).

PubMed  Article  Google Scholar 

Clift, A. K., Coupland, C. A. C. & Hippisley-Cox, J. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998–2017. Br. J. Gen. Pract. 71, e157–e165 (2021).